- Home
- FORA vs ARMP Comparison
FORA vs ARMP Comparison
Compare FORA & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FORA
- ARMP
- Stock Information
- Founded
- FORA 2014
- ARMP N/A
- Country
- FORA United States
- ARMP United States
- Employees
- FORA N/A
- ARMP N/A
- Industry
- FORA Computer Software: Prepackaged Software
- ARMP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FORA Technology
- ARMP Health Care
- Exchange
- FORA Nasdaq
- ARMP Nasdaq
- Market Cap
- FORA 64.0M
- ARMP 52.1M
- IPO Year
- FORA N/A
- ARMP N/A
- Fundamental
- Price
- FORA $2.15
- ARMP $1.91
- Analyst Decision
- FORA Strong Buy
- ARMP Strong Buy
- Analyst Count
- FORA 1
- ARMP 1
- Target Price
- FORA $5.00
- ARMP $9.00
- AVG Volume (30 Days)
- FORA 7.7K
- ARMP 36.4K
- Earning Date
- FORA 08-13-2025
- ARMP 08-12-2025
- Dividend Yield
- FORA N/A
- ARMP N/A
- EPS Growth
- FORA N/A
- ARMP N/A
- EPS
- FORA N/A
- ARMP N/A
- Revenue
- FORA $22,332,001.00
- ARMP $4,699,000.00
- Revenue This Year
- FORA $13.31
- ARMP $8.43
- Revenue Next Year
- FORA $43.65
- ARMP N/A
- P/E Ratio
- FORA N/A
- ARMP N/A
- Revenue Growth
- FORA 5.22
- ARMP 14.24
- 52 Week Low
- FORA $1.85
- ARMP $0.90
- 52 Week High
- FORA $4.03
- ARMP $3.42
- Technical
- Relative Strength Index (RSI)
- FORA 56.15
- ARMP 52.83
- Support Level
- FORA $1.95
- ARMP $1.74
- Resistance Level
- FORA $2.09
- ARMP $2.00
- Average True Range (ATR)
- FORA 0.11
- ARMP 0.15
- MACD
- FORA 0.01
- ARMP -0.03
- Stochastic Oscillator
- FORA 66.67
- ARMP 43.59
About FORA Forian Inc.
Forian Inc provides a suite of Software, data management capabilities, and proprietary data and analytics to optimize and measure operational, clinical, and financial performance for customers within the traditional and emerging life sciences, healthcare payer, and provider segments, as well as cannabis dispensaries, manufacturers, and cultivators.
About ARMP Armata Pharmaceuticals Inc.
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.